Alto Neuroscience (NYSE:ANRO - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.
Other analysts have also recently issued reports about the company. Zacks Research raised Alto Neuroscience from a "strong sell" rating to a "hold" rating in a research report on Thursday, August 20th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Alto Neuroscience in a research report on Wednesday, July 29th. HC Wainwright lifted their price objective on Alto Neuroscience from $50.00 to $55.00 and gave the company a "buy" rating in a research note on Monday, August 17th. Robert W. Baird lowered their price objective on Alto Neuroscience from $38.00 to $36.00 and set an "outperform" rating for the company in a research note on Monday, May 18th. Finally, Wolfe Research started coverage on Alto Neuroscience in a report on Friday, May 22nd. They issued an "outperform" rating on the stock. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $37.25.
Read Our Latest Stock Report on Alto Neuroscience
Alto Neuroscience Stock Down 3.2%
NYSE:ANRO opened at $35.13 on Friday. The firm's 50-day moving average price is $28.78 and its 200-day moving average price is $24.12. The company has a market capitalization of $1.38 billion, a PE ratio of -14.52 and a beta of 1.06. The company has a debt-to-equity ratio of 0.07, a current ratio of 14.85 and a quick ratio of 14.85. Alto Neuroscience has a 1-year low of $3.41 and a 1-year high of $37.48.
Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.08. On average, equities analysts predict that Alto Neuroscience will post -2.68 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of ANRO. AQR Capital Management LLC purchased a new stake in shares of Alto Neuroscience during the first quarter valued at approximately $52,000. Invesco Ltd. bought a new stake in shares of Alto Neuroscience during the first quarter valued at approximately $67,000. Bridgeway Capital Management LLC raised its holdings in Alto Neuroscience by 85.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company's stock worth $119,000 after acquiring an additional 25,000 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in Alto Neuroscience in the 4th quarter worth approximately $198,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Alto Neuroscience in the 4th quarter valued at approximately $221,000.
Alto Neuroscience Company Profile
(
Get Free Report)
Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.
Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Alto Neuroscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alto Neuroscience wasn't on the list.
While Alto Neuroscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
